The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Strides Pharma Science's Revenue for the
three
months ended in Mar. 2026 was ₹13,235 Mil. Strides Pharma Science's average Accounts Receivable for the
three
months ended in Mar. 2026 was ₹12,890 Mil.
Hence, Strides Pharma Science's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.03.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Strides Pharma Science Receivables Turnover Related Terms
Strides Pharma Science Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Strides Pharma Science's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:STAR vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strides Pharma Science (NSE:STAR) has a Receivables Turnover of 1.03 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Strides Pharma Science and its competitors. According to the industry distribution chart, Strides Pharma Science ranks #626 out of 950 companies in the Drug Manufacturers industry, placing it in the top 65.9%.
Is Strides Pharma Science's Receivables Turnover too high?
Strides Pharma Science's current Receivables Turnover is 1.03. The Drug Manufacturers industry median Receivables Turnover is 5.07. Strides Pharma Science's value of 1.03 is 79.7% below this industry median. Based on the distribution chart, Strides Pharma Science ranks #626 out of 950 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Strides Pharma Science has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Strides Pharma Science ranks #626 out of 950 companies for Receivables Turnover. This places Strides Pharma Science in the lower half of its industry. The industry median Receivables Turnover is 5.07. Strides Pharma Science's value of 1.03 is 79.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strides Pharma Science's current Receivables Turnover of 1.03 is 79.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Strides Pharma Science and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strides Pharma Science's current Receivables Turnover is 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹779.55, compared to a current price of ₹1,082.60 — trading 38.9% above its estimated fair value. The current Receivables Turnover is 1.03 and 79.7% below the Drug Manufacturers industry median of 5.07. Strides Pharma Science's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Receivables Turnover is 1.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,082.60 is trading 38.9% above its estimated GF Value™ of ₹779.55.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for NSE:STAR:
Receivables Turnover: 1.03
GF Value™: ₹779.55 vs. price of ₹1,082.60 (38.9% above fair value)
Industry Position: 79.7% below the Drug Manufacturers median (#626 of 950)
No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
74GF Score
Get the complete analysis for NSE:STAR
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:STAR has been successfully added to your 
